Harnessing heterogeneity in type 2 diabetes mellitus

Nat Rev Endocrinol. 2020 Feb;16(2):79-80. doi: 10.1038/s41574-019-0308-1.

Abstract

Personalized, or precision, medicine in type 2 diabetes mellitus is becoming a reality with new insights into the contributions of subgroup analyses. The roadmap to future implementation must take into account individual and subgroup variability in genetic architecture, environment, clinical measures, lifestyle, cost-effectiveness and treatment burden.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / metabolism*
  • Genetic Profile*
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Insulin Resistance / physiology*
  • PPAR gamma / agonists
  • PPAR gamma / metabolism
  • Precision Medicine / methods*
  • Precision Medicine / trends

Substances

  • Hypoglycemic Agents
  • PPAR gamma